US › Healthcare

Dare Bioscience Inc (DARE)

US · Healthcare · Biotechnology

$0.72-2.03%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$187,546

Net profit

$-3.0M

EPS

$-0.20

EPS estimate

$-0.33

Net margin

-1,590.4%

EPS came in at -0.20 against a street estimate of -0.33 — a beat of 39.4%.

Key statistics

Market cap

$14.4M

Forward P/E

1.3

P/B

29.40

Book value

$-0.04

EPS (TTM)

$-0.71

52-week high

$3.78

52-week low

$0.69

50-day MA

$0.87

200-day MA

$1.67

Beta

1.01

Analyst view

Analysts rate Dare Bioscience Inc a strong buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $8.33.

Shareholding

Insiders

12.08%

Institutions

13.37%

Largest institutional holders

Fund	Stake
Vanguard Capital Management, LLC	3.26%
Geode Capital Management, LLC	0.71%
U.S. Bancorp	0.61%
Vanguard Fiduciary Trust Co	0.46%
BlackRock Inc	0.33%
State Street Corp	0.24%
Jane Street Group LLC	0.18%
Northern Trust Corp	0.17%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Dare Bioscience Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-18.